Document is current

Article History

Received: 25 July 2025

Accepted: 5 September 2025

First Online: 25 October 2025

Declarations

:

: Eingun James Song is a consultant, promotional speaker and/or investigator for AbbVie, Alphyn, Alumis, Amgen, Apogee, Bristol Myers Squibb, CorEvitas, Dermavant, Dermbiont, Galderma, Incyte, Johnson & Johnson, Lilly, LEO, Moon Lake, Novartis, Organon, Ortho dermatologics, Pfize, Regeneron, Sanofi, SUN Pharma, UCB, Veradermics, Takeda, Target Registry Timber. Lindsay Ackerman has been an consultant, speaker, and/or investigator for AbbVie, Amgen, ArGEN-X, Artacus, AstraZeneca, Biofronterra, Bristol Myers Squibb, Castle, ChemoCentryx, Corevitas (Corrona), DermTech, Eli Lilly, Helsinn Incyte, Janssen, Kyowa Kirin, Mindera, Novartis, Sanofi, Sun, Timber, Trevi, and UCB. Benjamin Ehst is a speaker, adviser and/or clinical study investigator for AbbVie, Acelyrin, Allakos, Alumis, Amgen, Apogee, Arcutis, Bristol Myers Squibb, Celldex, Concert, Dermavant, Eli Lilly, Evelo Biosciences, Evommune, Incyte, Janssen, LEO, Merck, Navigator Medicines, Novartis, Pfizer, Takeda, Regeneron, Sanofi, Sun Pharma, UCB, and Ventyx. Phoebe Rich has served on advisory boards for Alumis, Oruka, and Veradermics and as an investigator for Abbvie, Aflasigma, Allakos, Amgen, Arcutis, Aslan, Bristol-Myers-Squibb, Dermavant, Dermbiont, Dermira, EliLilly, Galderma, Hallux, Incyte, Janssen, Leo, Moberg, Pfizer, Sun, Technoderma, Teva, UCB, and Veradermics. Jerry Bagel has received research funds from Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, Celgene, CorEvitas (Corrona) Psoriasis Registry, Dermavant, Dermira/UCB, Eli Lilly, Glenmark, Janssen Biotech, Kadmon, Leo Pharma, Lycera, Menlo Therapeutics, Novartis, Pfizer, Regeneron, Sun Pharma, Taro, and Valeant; has served as a consultant for AbbVie, Amgen, Celgene, Eli Lilly, Janssen Biotech, Novartis, Sun Pharma, and Valeant; and has served as a speaker for AbbVie, Celgene, Eli Lilly, Janssen Biotech, and Novartis. George Michael Lewitt is a consultant, promotional speaker, and/or investigator for AbbVie, Amgen, Arcutis, Bristol Meyers Squibb, Dermavant, Galderma Laboratories, Incyte, Janssen, Lilly, Novan, Novartis, Orthodermatologics, Pfizer, Sanofi, Sun Pharma, UCB, and the CorEvitas PsO and AD registries. Navid Ezra is a speaker, adviser and/or clinical study investigator for AbbVie, Alumis, Amgen, Arcutis, Boehringer Ingelheim, Bristol Myers Squibb, ChemoCentryx, Dermavant, Eli Lilly, Incyte, Janssen, LEO, Merck, Novartis, Ortho Dermatologics, Pfizer, Takeda, Regeneron, Sanofi, Sun Pharma, UCB and the CorEvitas registries. Brad Glick is an advisory board member, consultant, speaker and/or investigator for and received honoraria or grants from Amgen, AbbVie, AstraZeneca, Almirall, Acrutis, Bausch Health/Valeant, OrthoDermatologics, Boehringer Ingelheim, Bristol Myers Squibb, Brickell Biotech, Cara Therapeutics, ChemoCentryx, Dermavant, Dermira, Eli Lilly, EPI/Novan Pharmaceuticals, Incyte, Janssen Pharmaceuticals, LEO Pharma, Galderma, Nimbus Lakshmi, Inc, Novartis Pharmaceutical Corporation, Sun Pharma, Pfizer, Sanofi, Regeneron, UCB Biopharmaceuticals and the CorEvitas AD, CorEvitas PSO and PROSE Registries. Dr. Glick is a shareholder of Top MD, LLC. Toni Anschutz, Brenton Bialik, Greg St. John, Arathi Setty, Chenyang Duan, Manish Patel, and Doug Ashley are full time employees of AbbVie receiving a salary and may hold stock and/or stock options.

: Study approval was obtained from local ethics committees (Advarra, reference numbers available in the supplementary materials), and the patients provided written informed consent for participation in the study and publication of study data. The study was conducted in accordance with the International Conference on Harmonisation, Good Clinical Practice Guidelines, and the Declaration of Helsinki 1964 and its later amendments.